Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Liver Dis ; 23(3): 511-519, 2019 08.
Article in English | MEDLINE | ID: mdl-31266624

ABSTRACT

Patients with malignancies require chemotherapy and other immunosuppressive therapies for treatment. Because of this immunosuppression, in patients who have ever been exposed to hepatitis B it is possible for reactivation to occur. This reactivation can be fatal. Reactivation is particularly likely in patients who receive B cell-active agents such as rituximab. The occurrence of reactivation flares may also delay further chemotherapy, which can negatively affect the outcome of the underlying malignancy. Accordingly, it is important to screen patients for markers of hepatitis B and institute antiviral prophylaxis to prevent reactivation.


Subject(s)
Hematologic Neoplasms/epidemiology , Hepatitis B virus/physiology , Hepatitis B, Chronic/prevention & control , Immunocompromised Host , Neoplasms/epidemiology , Virus Activation/immunology , Cause of Death , Female , Hematologic Neoplasms/immunology , Hepatitis B Antibodies/immunology , Hepatitis B, Chronic/epidemiology , Hepatitis B, Chronic/physiopathology , Humans , Male , Mass Screening , Neoplasms/immunology , Prevalence , Primary Prevention/methods , Prognosis , Risk Assessment , Survival Analysis , Virus Activation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...